BUSINESS
AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
AstraZeneca (AZ) K.K. and Bristol-Myers K.K. (BMKK) announced on April 1 that Eli Lilly Japan transferred the marketing rights for its type 2 diabetes treatments Byetta and Bydureon, glucagon-like peptide-1 (GLP-1) receptor agonists both containing exenatide, to AZ K.K. Bydureon…
To read the full story
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





